Neurogene shares reached a 52-week high after the genetic medicine company announced an oversubscribed private placement of about $200 million. The stock was up 44% to $66.55 on Monday, with an ...

The news led to a stock surge on expectations that forthcoming data for the company’s experimental gene therapy for Rett ...

The company will use the funds to enroll a registrational trial for its investigational gene therapy NGN-401 for Rett Syndrome.

The influx of these investments into India is a direct result of the government's proactive policy framework, a dynamic business environment, improving global competitiveness, and a burgeoning ...

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and ...